BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 24809932)

  • 1. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
    Chen J; Chen Y; Luo Y; Gui D; Huang J; He D
    Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
    Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L
    BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression.
    Gui D; Huang J; Guo Y; Chen J; Chen Y; Xiao W; Liu X; Wang N
    Cytokine; 2013 Mar; 61(3):970-7. PubMed ID: 23434274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notoginsenoside R1 ameliorates podocyte adhesion under diabetic condition through α3β1 integrin upregulation in vitro and in vivo.
    Gui D; Wei L; Jian G; Guo Y; Yang J; Wang N
    Cell Physiol Biochem; 2014; 34(6):1849-62. PubMed ID: 25503068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats.
    Fan Y; Fan H; Zhu B; Zhou Y; Liu Q; Li P
    BMC Complement Altern Med; 2019 Dec; 19(1):355. PubMed ID: 31805910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of tacrolimus on podocytes in early diabetic nephropathy in rats.
    Peng T; Chang X; Wang J; Zhen J; Yang X; Hu Z
    Mol Med Rep; 2017 May; 15(5):3172-3178. PubMed ID: 28339051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Astragaloside IV on diabetic nephropathy in rats.
    Lu WS; Li S; Guo WW; Chen LL; Li YS
    Genet Mol Res; 2015 May; 14(2):5427-34. PubMed ID: 26125738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via alpha3beta1 integrin upregulation and integrin-linked kinase inhibition.
    Chen J; Gui D; Chen Y; Mou L; Liu Y; Huang J
    Biochem Pharmacol; 2008 Sep; 76(6):796-804. PubMed ID: 18652804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
    Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway.
    Lei X; Zhang BD; Ren JG; Luo FL
    Life Sci; 2018 Aug; 206():77-83. PubMed ID: 29792879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy.
    Xing L; Fang J; Zhu B; Wang L; Chen J; Wang Y; Huang J; Wang H; Yao X
    Life Sci; 2021 Mar; 269():119068. PubMed ID: 33476631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emodin ameliorates high glucose induced-podocyte epithelial-mesenchymal transition in-vitro and in-vivo.
    Chen T; Zheng LY; Xiao W; Gui D; Wang X; Wang N
    Cell Physiol Biochem; 2015; 35(4):1425-36. PubMed ID: 25791065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats.
    Chen Y; Gui D; Chen J; He D; Luo Y; Wang N
    Cell Physiol Biochem; 2014; 33(6):1975-87. PubMed ID: 25012492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation.
    Zhang Y; Tao C; Xuan C; Jiang J; Cao W
    Oxid Med Cell Longev; 2020; 2020():9542165. PubMed ID: 32855769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy.
    Guo H; Wang Y; Zhang X; Zang Y; Zhang Y; Wang L; Wang H; Wang Y; Cao A; Peng W
    Sci Rep; 2017 Jul; 7(1):6852. PubMed ID: 28761152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.
    Song G; Han P; Sun H; Shao M; Yu X; Wang W; Wang D; Yi W; Ge N; Li S; Yi T
    J Int Med Res; 2018 Jul; 46(7):2883-2897. PubMed ID: 29896981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
    Zhang M; Liu M; Xiong M; Gong J; Tan X
    J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
    Wang S; Li Y; Zhao J; Zhang J; Huang Y
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
    Wang S; Li Y; Huang YJ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats.
    Qi MY; Kai-Chen ; Liu HR; Su YH; Yu SQ
    J Ethnopharmacol; 2011 Dec; 138(3):731-6. PubMed ID: 22027446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.